LPTX Stock Risk & Deep Value Analysis

LPTX

Healthcare • Biotechnology

DVR Score

2.6

out of 10

Risk Trap

The Bottom Line on LPTX

We analyzed LPTX using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran LPTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Jan 25, 2026•Run Fresh Analysis →

LPTX Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

High

About LPTX (LPTX)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$62.88M

LPTX Deep Value Analysis

Leap Therapeutics (LPTX) remains a deeply speculative, high-risk, high-reward biopharmaceutical company with a score of 26/100. This score remains consistent with the previous analysis as no material changes have occurred in the past 7 days. The potential for a 10x return hinges almost entirely on breakthrough clinical trial readouts for DKN-01 (Phase 2 for gastric/GEJ cancers), which are inherently binary and carry immense risk. While the market opportunity in oncology is significant and the strategic vision for DKN-01 is clear, competitive advantages are still nascent and dependent on definitive positive clinical data. Financial health continues to be a critical concern due to ongoing burn, despite likely successful dilutive financing into late 2026. Without a major efficacy inflection point, the path to significant value creation remains extremely challenging.

LPTX Red Flags & Warning Signs

  • âš 

    Negative or inconclusive clinical trial results for DKN-01

  • âš 

    Need for further dilutive financing earlier than anticipated

  • âš 

    Increased competition in the gastric/GEJ cancer therapeutic landscape

Unlock LPTX Red Flags & Risk Warnings

Create a free account to see the full analysis

LPTX Financial Health Metrics

Market Cap

$62.88M

LPTX Competitive Moat Analysis

Sign in to unlock

Moat Rating

None

Moat Trend

Eroding

Moat Sources

1 Identified

Intangible Assets/IP

The company's intellectual property around DKN-01 forms the only potential moat, but its durability is entirely dependent on successful clinical trial outcomes and subsequent regulatory approval. Without definitive positive data, the IP offers little real-world competitive advantage, and the trend is eroding as development costs mount without commercialization.

LPTX Competitive Moat Analysis

Sign up to see competitive advantages

LPTX Catalysts & Growth Drivers

Near-Term (0-6 months)

  • •Q4 2025 Earnings Report (Estimated late February/early March 2026)
  • •Updates on DKN-01 trial enrollment and progression

Medium-Term (6-18 months)

  • •Interim Phase 2 data readouts for DKN-01 in gastric/GEJ cancer (mid-2026)
  • •Potential strategic partnership or licensing discussions based on early data

Long-Term (18+ months)

  • •Full Phase 2 data readout and decision on Phase 3 advancement (late 2026/early 2027)
  • •Potential expansion of DKN-01 into additional solid tumor indications

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

LPTX Bull Case: What Could Go Right

  • ✓

    Significant positive interim or final Phase 2 clinical data for DKN-01 (efficacy and safety endpoints).

  • ✓

    Announcement of a strategic partnership, licensing agreement, or acquisition offer.

  • ✓

    Successful, non-dilutive financing or significant insider buying.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.

More Resources to Boost Your Portfolio

Explore our other guides and tools to maximize your investment returns

5-Minute Guide Thumbnail

6 Simple Steps Spotting Undervalued Stocks

Learn More
Dividend Stocks Thumbnail

Earn $500/Month with Dividend Stocks

Learn More
Swing Trading Guide Thumbnail

3 Swing Trading Strategies for Predictable Gains

Learn More